Jade Biosciences, Inc. (JBIO)

Jade Biosciences, Inc. (JBIO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $853M; returns 1 day -2.1%, 1 week +8.3%, 1 year +46.9%.

Jade Biosciences, Inc. (JBIO) is a clinical-stage biotechnology company dedicated to developing best-in-class therapies for autoimmune diseases. Launched in mid-2024, Jade's pipeline is built upon licensed assets, particularly monoclonal antibodies, from companies like Paragon Therapeutics.

Groups JBIO belongs to

• Biotechnology
• Autoimmune Diseases
• Clinical Stage
• Clinical Stage Biotech
• Healthcare
• Monoclonal Antibodies
• Biologics
• Nephrology
• Rheumatoid Arthritis
• Pharmaceuticals

JBIO financial model: income statement, cash flow and balance sheet